Controladoria de gestão na PREVI: modelos, apoio à governança e Lei complementar 108

O segmento de previdência privada fechada tem 3,2 milhões de participantes e assistidos com mais de 1.000 planos de previdência administrados por 330 fundos de pensão (EFPC). Para que essas entidades cumpram a sua missão é necessário um acompanhamento dos recursos acumulados, do desempenho atingido pelos investimentos e a avaliação de se o montante acumulado permite o complemento de renda esperado, e também se faz necessário que os participantes dos planos de previdência tenham acesso às informações de sua performance. Este trabalho abordará o estudo desses fundos de pensão, com foco naqueles cujo patrocínio é de uma entidade pública regida pela Lei Complementar nº108/2001, que disciplina a relação dessas entidades públicas, enquanto patrocinadoras, com suas respectivas entidades fechadas de previdência privada. Há diferenças significativas entre os fundos de pensão e as demais empresas, porém os fundos de pensão passam por problemas similares nos aspectos de gestão e governança. Este trabalho analisará a governança dos fundos de pensão e o papel e atribuições da área de Controladoria, normalmente a responsável por gerar informações para alta administração das empresas em geral, adaptando-as ao contexto da previdência. Como caso prático, será analisada a PREVI - Fundo de Pensão dos Funcionários do Banco do Brasil e sua área de controladoria. A PREVI é uma entidade fechada de previdência complementar, fundada há 109 anos, maior fundo de pensão de América Latina e o 27o do mundo. Atualmente administra três planos de previdência que totalizam mais de R$ 160 bilhões em ativos.

Robert Philips Lane Papers - Accession 108

The Robert Philips Lane Papers consist of lecture notes, term papers, examinations, class rolls, seating charts, speech notes and papers relating to Dr. Lane’s career as an English professor at Winthrop. Comprising a significant portion of the collection are research notes, writings, research papers, and other notes on literary figures and genres while Dr. Robert Philip Lane was a student at Thayer Academy, Harvard University, and the University of North Carolina.

108 Sn studied with intermediate-energy Coulomb excitation

In dieser Arbeit wurde der instabile, Neutronenarme Kern 108Sn mit Hilfe der Coulomb-Anregung bei intermediaeren Energien in inverser Kinematik studiert. Diese Methode wurde bisher zur Untersuchung der ersten angeregten 2+ Zustaende und deren E2 Zerfallsraten in Kernen mit Kernladungszahl Z< 30 angewendet. 108Sn ist somit der Kern mit der groeßten Kernladungszahl, bei dem diese Studien bisher stattfanden. Das Ziel dieses Experiments war die Messung der unbekannten reduzierten Uebergangswahrscheinlichkeit B(E2,0+ -> 2+). Der B(E2)-Wert von 0.230(57) e2b2 wurde relativ zu dem bekannten Wert des Isotops 112Sn bestimmt. Das Experiment wurde an der GSI Darmstadt mit Hilfe des RISING Detektors und des Fragmentseperators (FRS) durchgefuehrt. Sekundaere Strahlen (108Sn, 112Sn) mit einer Energie von ca. 150 MeV pro Nukleon wurden auf ein 386 mg/cm2 dickes 197Au Target geschossen. Die Projektilfragmente wurden mit Hilfe des Fragmentseparators selektiert und identifiziert. Zur Selektion des Reaktionskanals und zur Bestimmung des Winkels der gestreuten Fragmente wurde das Teilchenteleskop CATE, das sich hinter dem Target befand, verwendet. Gammastrahlung, die in Koinzidenz mit den Projektilrestkernen emittiert wurde, wurde in den Germanium-Cluster Detektoren des RISING Detektors nachgewiesen. Der gemessene B(E2,0+ -> 2+)-Wert von 108Sn ist in Uebereinstimmung mit neueren Schalenmodellrechnungen, die auf realistischen effektiven Wechselwirkungen basieren und im Rahmen eines verallgemeinerten Seniorit¨ats-Schemas erklaert werden.

Dose escalation and pharmacokinetic study of AEZS-108 (AN-152), an LHRH agonist linked to doxorubicin, in women with LHRH receptor-positive tumors

Receptors for luteinizing hormone-releasing hormone (LHRH) can be utilized for targeted chemotherapy of cytotoxic LHRH analogs. The compound AEZS-108 (previously AN-152) consists of [D-Lys?]LHRH linked to doxorubicin. The objectives of this first study in humans with AESZ-108 were to determine the maximum tolerated dose and to characterize the dose-limiting toxicity, pharmacokinetics, preliminary efficacy, and hormonal effects.

Clinical and echocardiographic features of mild mitral valve regurgitation in 108 horses

The clinical and echocardiographic characteristics of 108 horses with echocardiographically confirmed mild mitral valve regurgitation (MR) were investigated along with its clinical progression. Follow-up consisted of a re-examination of 28 horses and questionnaires were used to obtain information on a further 43 cases. Thirty-seven horses with mild MR were lost to follow-up. Horses with mild MR were re-examined between 2 and 9 years (3.8+/-1.8 years) following first presentation, with mild MR still present and a small, but statistically significant (P=0.049) increase of left ventricular diameter in end-diastole. These results suggested that mild MR has a good mid-term prognosis in sport and pleasure horses.

Ms. Barth. 108 - Rationale divinorum officiorum abbreviatum (Collectorium)

Vorbesitzer: Johannes Blasbalg; Bartholomaeusstift Frankfurt am Main

The effectiveness and safety of rescue treatments in 108 patients with steroid-refractory ulcerative colitis with sequential rescue therapies in a subgroup of patients

BACKGROUND: Among patients with steroid-refractory ulcerative colitis (UC) in whom a first rescue therapy has failed, a second line salvage treatment can be considered to avoid colectomy. AIM: To evaluate the efficacy and safety of second or third line rescue therapy over a one-year period. METHODS: Response to single or sequential rescue treatments with infliximab (5mg/kg intravenously (iv) at week 0, 2, 6 and then every 8weeks), ciclosporin (iv 2mg/kg/daily and then oral 5mg/kg/daily) or tacrolimus (0.05mg/kg divided in 2 doses) in steroid-refractory moderate to severe UC patients from 7 Swiss and 1 Serbian tertiary IBD centers was retrospectively studied. The primary endpoint was the one year colectomy rate. RESULTS: 60% of patients responded to the first rescue therapy, 10% went to colectomy and 30% non-responders were switched to a 2(nd) line rescue treatment. 66% of patients responded to the 2(nd) line treatment whereas 34% failed, of which 15% went to colectomy and 19% received a 3(rd) line rescue treatment. Among those, 50% patients went to colectomy. Overall colectomy rate of the whole cohort was 18%. Steroid-free remission rate was 39%. The adverse event rates were 33%, 37.5% and 30% for the first, second and third line treatment respectively. CONCLUSION: Our data show that medical intervention even with 2(nd) and 3(rd) rescue treatments decreased colectomy frequency within one year of follow up. A longer follow-up will be necessary to investigate whether sequential therapy will only postpone colectomy and what percentage of patients will remain in long-term remission.

Ms. lat. qu. 108 - Relazionen und Depeschen aus Rom

Die Foliierung geht nur bis Bl. 422; zusätzlich gibt es das Blatt 98a.